ABVC BioPharma, Inc. announced a plan to separate BioKey (Cayman), Inc. through a spin-off and pro rata distribution of 15% of Subsidiary's ordinary shares to Parent shareholders. The move aims to enhance shareholder value by separating the two distinct businesses.